Singh Sheo B, Kaelin David E, Meinke Peter T, Wu Jin, Miesel Lynn, Tan Christopher M, Olsen David B, Lagrutta Armando, Fukuda Hideyuki, Kishii Ryuta, Takei Masaya, Takeuchi Tomoko, Takano Hisashi, Ohata Kohei, Kurasaki Haruaki, Nishimura Akinori, Shibata Takeshi, Fukuda Yasumichi
Merck Research Laboratories, Kenilworth, NJ 07033, United States.
Merck Research Laboratories, Kenilworth, NJ 07033, United States.
Bioorg Med Chem Lett. 2015 Sep 1;25(17):3630-5. doi: 10.1016/j.bmcl.2015.06.061. Epub 2015 Jun 23.
Oxabicyclooctane linked novel bacterial topoisomerase inhibitors (NBTIs) are new class of recently reported broad-spectrum antibacterial agents. They target bacterial DNA gyrase and topoisomerase IV and bind to a site different than quinolones. They show no cross-resistance to known antibiotics and provide opportunity to combat drug-resistant bacteria. A structure activity relationship of the C-2 substituted ether analogs of 1,5-naphthyridine oxabicyclooctane-linked NBTIs are described. Synthesis and antibacterial activities of a total of 63 analogs have been summarized representing alkyl, cyclo alkyl, fluoro alkyl, hydroxy alkyl, amino alkyl, and carboxyl alkyl ethers. All compounds were tested against three key strains each of Gram-positive and Gram-negative bacteria as well as for hERG binding activities. Many key compounds were also tested for the functional hERG activity. Six compounds were evaluated for efficacy in a murine bacteremia model of Staphylococcus aureus infection. Significant tolerance for the ether substitution (including polar groups such as amino and carboxyl) at C-2 was observed for S. aureus activity however the same was not true for Enterococcus faecium and Gram-negative strains. Reduced clogD generally showed reduced hERG activity and improved in vivo efficacy but was generally associated with decreased overall potency. One of the best compounds was hydroxy propyl ether (16), which mainly retained the potency, spectrum and in vivo efficacy of AM8085 associated with the decreased hERG activity and improved physical property.
氧杂双环辛烷连接的新型细菌拓扑异构酶抑制剂(NBTIs)是最近报道的一类新型广谱抗菌剂。它们靶向细菌DNA促旋酶和拓扑异构酶IV,并结合到与喹诺酮类不同的位点。它们对已知抗生素无交叉耐药性,为对抗耐药细菌提供了机会。本文描述了1,5-萘啶氧杂双环辛烷连接的NBTIs的C-2取代醚类似物的构效关系。总结了总共63种类似物的合成及抗菌活性,这些类似物包括烷基、环烷基、氟烷基、羟烷基、氨基烷基和羧基烷基醚。所有化合物均针对革兰氏阳性和革兰氏阴性细菌的三种关键菌株进行了测试,以及检测了其对人醚-去极化激活的钾离子通道(hERG)的结合活性。许多关键化合物还进行了功能性hERG活性测试。评估了六种化合物在金黄色葡萄球菌感染的小鼠菌血症模型中的疗效。对于金黄色葡萄球菌的活性,观察到对C-2位醚取代(包括氨基和羧基等极性基团)有显著耐受性,然而对于粪肠球菌和革兰氏阴性菌株则并非如此。一般来说, clogD降低表明hERG活性降低和体内疗效提高,但通常与整体效力降低有关。其中一种最佳化合物是羟丙基醚(16),它主要保留了AM8085的效力、谱效关系和体内疗效,同时降低了hERG活性并改善了物理性质。